HIV/TB Research Frontiers Meeting in conjunction with CROI 2016

Monday, 22 February 2016, 11:30-13:30
Sheraton Boston Hotel, Fairfax Room, 39 Dalton Street, Boston, MA 02199, USA

Organized by the World Health Organization

AGENDA

11:30-11:40: Introduction and opening remarks

11:40-12:00: Global Data from novel WHO surveillance of PZA and fluroquinolone resistance
Matteo Zignol, WHO Switzerland

12:00-12:05: Question and answer for clarification

12:05-12:25: Implications for ongoing research and the design of future clinical trials
Rada Savic, University of California, San Francisco, USA

12:25-12:30: Question and answer for clarification

12:30-12:35: Commentary on first presentation
Eric Nuermberger, Johns Hopkins Medicine, USA

12:35-12:40: Commentary on second presentation
Mel Spigelman, TB Alliance, USA

12:40-13:25: Discussion

13:25-13:30: General conclusion and next steps
HIV/TB Roadmap at CROI 2016

Monday, February 22, 2016
Opening Session, 17:00-19:00, Auditorium
14: Confronting HIV and TB from the Bronx, NY, to Tugela Ferry, South Africa, Gerald H. Friedland

Tuesday, February 23, 2016
Global Burden and Mortality of Cancer in HIV - Session TD-2 Themed Discussion, 13:45 – 14:45, Room 312
615: Cancer versus TB mortality among HIV-infected individuals in Botswana, Scott Dryden-Peterson, et al

Wednesday, February 24, 2016
Session 0-10 Oral Abstracts, 10:00–12:00, Ballroom A
11:00 115: Optimising South Africa’s HIV Response: Results of the HIV and TB Investment Case, Calvin Chiu, et al

Thursday, February 25, 2016
Plenary Session, 08:30–09:30, Auditorium
08:30 131: Tuberculosis: Why do I have to take so many pills? Eric J Rubin

Tuberculosis and Other Opportunistic infections/Cancer Prevention: Hits and Misses - Session 0-14 Oral Abstracts, 10:00-12:00, Ballroom A
10:00 155: Empirical TB treatment in advanced HIV disease: Results of the TB Fast Track Trial, Alison Grant, et al
10:45 158LB: Beta-lactams against TB: Teaching a new trick to an old dog, Andreas H Diacon, et al

Poster Sessions
All poster sessions will be held from 14:45-16:00 on the scheduled days
P-R1: Tuberculosis: Pathogenesis studies, 733-734, 764, 806-810, 816ib
P-R2: Tuberculosis transmission, 735, 737, 746, 810, 811ib, 812-815, 817- 821
P-R3: Implementation of HIV and TB services, 738-740, 816-818, 822-826, 827LB, 828LB
P-R4: TB related outcomes and mortality, 742-746, 819-824, 829
P-R5: Diagnosis of tuberculosis, 747-750, 825-827, 829- 833
P-R6: Tuberculosis and antiretroviral therapy, 751-753
P-R7: Multidrug-resistant tuberculosis, 754-756
P-R8: Tuberculosis and pregnancy, 757-758
P-O1: Global burden and mortality of cancer in HIV, 615
P-Y3: Modelling the cost efficiency of testing and prevention, 1053
P-G2: Virology and basic neuroscience, 398
P-R10: Other infectious complications of HIV disease, 764
P-HS: Clinical pharmacology of treating coinfections, 456-459, 532,